Investigation of Drug–Excipient Interactions in Lapatinib Amorphous Solid Dispersions Using Solid-State NMR Spectroscopy

This study investigated the presence of specific drug–excipient interactions in amorphous solid dispersions of lapatinib (LB) and four commonly used pharmaceutical polymers, including Soluplus, polyvinylpyrrolidone vinyl acetate (PVPVA), hydroxypropylmethylcellulose acetate succinate (HPMCAS), and h...

Full description

Saved in:
Bibliographic Details
Published inMolecular pharmaceutics Vol. 12; no. 3; pp. 857 - 866
Main Authors Song, Yang, Yang, Xinghao, Chen, Xin, Nie, Haichen, Byrn, Stephen, Lubach, Joseph W
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 02.03.2015
Subjects
Online AccessGet full text

Cover

Loading…
Abstract This study investigated the presence of specific drug–excipient interactions in amorphous solid dispersions of lapatinib (LB) and four commonly used pharmaceutical polymers, including Soluplus, polyvinylpyrrolidone vinyl acetate (PVPVA), hydroxypropylmethylcellulose acetate succinate (HPMCAS), and hydroxypropylmethylcellulose phthalate (HPMCP). Based on predicted pK a differences, LB was hypothesized to exhibit a specific ionic interaction with HPMCP, and possibly with HPMCAS, while Soluplus and PVPVA were studied as controls without ionizable functionality. Thermal studies showed a single glass transition (T g) for each dispersion, in close agreement with predicted values for Soluplus, PVPVA, and HPMCAS systems. However, the T g values of LB–HPMCP solid dispersions were markedly higher than predicted values, indicating a strong intermolecular interaction between LB and HPMCP. 15N solid-state NMR provided direct spectroscopic evidence for protonation of LB (i.e., salt formation) within the HPMCP solid dispersions. 1H T 1 and 1H T 1ρ relaxation studies of the dispersions supported the ionic interaction hypothesis, and indicated multiple phases in the cases of excess drug or polymer. In addition, the dissolution and stability behavior of each system was examined. Both acidic polymers, HPMCAS and HPMCP, effectively inhibited the crystallization of LB on accelerated stability, likely owing to beneficial strong intermolecular hydrogen and/or specific ionic bonds with the acidic polymers. Soluplus and PVPVA showed poor physical properties on stability and subsequently poor crystallization inhibition.
AbstractList This study investigated the presence of specific drug-excipient interactions in amorphous solid dispersions of lapatinib (LB) and four commonly used pharmaceutical polymers, including Soluplus, polyvinylpyrrolidone vinyl acetate (PVPVA), hydroxypropylmethylcellulose acetate succinate (HPMCAS), and hydroxypropylmethylcellulose phthalate (HPMCP). Based on predicted pKa differences, LB was hypothesized to exhibit a specific ionic interaction with HPMCP, and possibly with HPMCAS, while Soluplus and PVPVA were studied as controls without ionizable functionality. Thermal studies showed a single glass transition (Tg) for each dispersion, in close agreement with predicted values for Soluplus, PVPVA, and HPMCAS systems. However, the Tg values of LB-HPMCP solid dispersions were markedly higher than predicted values, indicating a strong intermolecular interaction between LB and HPMCP. (15)N solid-state NMR provided direct spectroscopic evidence for protonation of LB (i.e., salt formation) within the HPMCP solid dispersions. (1)H T1 and (1)H T1ρ relaxation studies of the dispersions supported the ionic interaction hypothesis, and indicated multiple phases in the cases of excess drug or polymer. In addition, the dissolution and stability behavior of each system was examined. Both acidic polymers, HPMCAS and HPMCP, effectively inhibited the crystallization of LB on accelerated stability, likely owing to beneficial strong intermolecular hydrogen and/or specific ionic bonds with the acidic polymers. Soluplus and PVPVA showed poor physical properties on stability and subsequently poor crystallization inhibition.
This study investigated the presence of specific drug–excipient interactions in amorphous solid dispersions of lapatinib (LB) and four commonly used pharmaceutical polymers, including Soluplus, polyvinylpyrrolidone vinyl acetate (PVPVA), hydroxypropylmethylcellulose acetate succinate (HPMCAS), and hydroxypropylmethylcellulose phthalate (HPMCP). Based on predicted pK a differences, LB was hypothesized to exhibit a specific ionic interaction with HPMCP, and possibly with HPMCAS, while Soluplus and PVPVA were studied as controls without ionizable functionality. Thermal studies showed a single glass transition (T g) for each dispersion, in close agreement with predicted values for Soluplus, PVPVA, and HPMCAS systems. However, the T g values of LB–HPMCP solid dispersions were markedly higher than predicted values, indicating a strong intermolecular interaction between LB and HPMCP. 15N solid-state NMR provided direct spectroscopic evidence for protonation of LB (i.e., salt formation) within the HPMCP solid dispersions. 1H T 1 and 1H T 1ρ relaxation studies of the dispersions supported the ionic interaction hypothesis, and indicated multiple phases in the cases of excess drug or polymer. In addition, the dissolution and stability behavior of each system was examined. Both acidic polymers, HPMCAS and HPMCP, effectively inhibited the crystallization of LB on accelerated stability, likely owing to beneficial strong intermolecular hydrogen and/or specific ionic bonds with the acidic polymers. Soluplus and PVPVA showed poor physical properties on stability and subsequently poor crystallization inhibition.
Author Yang, Xinghao
Lubach, Joseph W
Chen, Xin
Song, Yang
Nie, Haichen
Byrn, Stephen
AuthorAffiliation Nanjing Normal University
GlaxoSmithKline
Genentech, Inc
Small Molecule Pharmaceutical Sciences
Purdue University
College of Life Sciences
Department of Industrial and Physical Pharmacy
AuthorAffiliation_xml – name: Small Molecule Pharmaceutical Sciences
– name: Genentech, Inc
– name: Nanjing Normal University
– name: College of Life Sciences
– name: Department of Industrial and Physical Pharmacy
– name: Purdue University
– name: GlaxoSmithKline
Author_xml – sequence: 1
  givenname: Yang
  surname: Song
  fullname: Song, Yang
– sequence: 2
  givenname: Xinghao
  surname: Yang
  fullname: Yang, Xinghao
– sequence: 3
  givenname: Xin
  surname: Chen
  fullname: Chen, Xin
– sequence: 4
  givenname: Haichen
  surname: Nie
  fullname: Nie, Haichen
– sequence: 5
  givenname: Stephen
  surname: Byrn
  fullname: Byrn, Stephen
– sequence: 6
  givenname: Joseph W
  surname: Lubach
  fullname: Lubach, Joseph W
  email: lubach.joseph@gene.com
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25585133$$D View this record in MEDLINE/PubMed
BookMark eNptkEFOwzAQRS0EAgosuADyBgkWATuOU2eJ2gKVCkgU1pHrTopRYxs7QZQVd-CGnASXQlfMZkYzT19_fgdtGmsAoUNKzihJ6XntOCF5kcoNtEt5xhLBinRzPYtsB3VCeCYkzXjKttFOyrnglLFd9D40rxAaPZONtgbbCvd9O_v6-By8Ke00mAYPTQNequU9YG3wSLoIGz3BF7X17sm2AY_tXE9xXwcHPvyAj0Gb2WqfjBvZAL69ucdjB6rxNijrFvtoq5LzAAe_fQ89Xg4eetfJ6O5q2LsYJZIJ2iRCdFUBUsGkIBXPIBNKZgRoRTmfQpdNKeQUsm5ayEgRELmAXHEQXKZcKMb20MlK13n70sZny1oHBfO5NBC9lzTPScZikYierlAVPQYPVem8rqVflJSUy6jLddSRPfqVbSc1TNfkX7YROF4BUoXy2bbexC__EfoGtK-KNg
CitedBy_id crossref_primary_10_1007_s11095_023_03483_3
crossref_primary_10_1021_acs_molpharmaceut_6b00740
crossref_primary_10_1021_acs_molpharmaceut_7b00039
crossref_primary_10_1021_acs_molpharmaceut_0c01054
crossref_primary_10_1016_j_ijpharm_2019_05_028
crossref_primary_10_1016_j_ijpharm_2023_123536
crossref_primary_10_1016_j_xphs_2019_12_005
crossref_primary_10_1021_acs_cgd_8b00203
crossref_primary_10_1007_s13346_023_01473_x
crossref_primary_10_1016_j_ajps_2024_100900
crossref_primary_10_1021_acs_molpharmaceut_9b00186
crossref_primary_10_1016_j_jddst_2023_104559
crossref_primary_10_3390_pharmaceutics13010097
crossref_primary_10_1155_2017_4537632
crossref_primary_10_3390_pharmaceutics11040159
crossref_primary_10_1016_j_ejpb_2017_06_003
crossref_primary_10_1016_j_genrep_2024_101897
crossref_primary_10_1208_s12249_020_01891_x
crossref_primary_10_1016_j_ejps_2016_08_048
crossref_primary_10_1016_j_jconrel_2016_08_036
crossref_primary_10_1021_acs_molpharmaceut_3c00226
crossref_primary_10_1208_s12249_019_1358_3
crossref_primary_10_1016_j_ijpharm_2015_08_068
crossref_primary_10_1007_s11094_017_1679_z
crossref_primary_10_1021_acs_molpharmaceut_8b00021
crossref_primary_10_1021_acs_molpharmaceut_9b00731
crossref_primary_10_1016_j_ejps_2019_02_005
crossref_primary_10_1021_acs_molpharmaceut_9b00970
crossref_primary_10_1016_j_ssnmr_2022_101796
crossref_primary_10_1021_acs_cgd_9b00708
crossref_primary_10_1021_acs_molpharmaceut_9b00174
crossref_primary_10_1021_acs_molpharmaceut_1c00288
crossref_primary_10_1021_acs_molpharmaceut_6b00960
crossref_primary_10_1021_acs_chemrev_2c00197
crossref_primary_10_1016_j_jddst_2019_101362
crossref_primary_10_1016_j_ijpharm_2016_06_126
crossref_primary_10_1021_acs_molpharmaceut_5b00708
crossref_primary_10_1002_mrc_4984
crossref_primary_10_1007_s12668_024_01348_6
crossref_primary_10_1016_j_xphs_2022_07_020
crossref_primary_10_1016_j_jddst_2022_104059
crossref_primary_10_1016_j_ejps_2018_03_033
crossref_primary_10_1007_s11095_018_2364_y
crossref_primary_10_1021_acs_molpharmaceut_5b00162
crossref_primary_10_1021_acs_molpharmaceut_7b00804
crossref_primary_10_1021_acs_molpharmaceut_2c00970
crossref_primary_10_1016_j_xphs_2020_12_033
crossref_primary_10_1016_j_xphs_2015_10_008
crossref_primary_10_1208_s12249_018_1060_x
crossref_primary_10_1016_j_trac_2020_116152
crossref_primary_10_3390_polym14245557
crossref_primary_10_1016_j_ijpharm_2017_11_056
crossref_primary_10_1016_j_ijpharm_2018_09_062
crossref_primary_10_1016_j_xphs_2021_05_020
crossref_primary_10_1039_C6CP02855A
crossref_primary_10_1021_acs_molpharmaceut_5b00333
crossref_primary_10_1016_j_xphs_2017_03_006
crossref_primary_10_3390_biomimetics6010001
crossref_primary_10_1016_j_heliyon_2023_e23221
crossref_primary_10_1016_j_ijpharm_2021_120500
crossref_primary_10_1007_s11814_022_1280_3
crossref_primary_10_1111_jphp_12515
crossref_primary_10_1016_j_addr_2017_07_001
crossref_primary_10_1021_acs_molpharmaceut_9b00301
crossref_primary_10_1002_mrc_4688
crossref_primary_10_1039_D1CC02110A
crossref_primary_10_1080_03639045_2020_1764026
crossref_primary_10_1208_s12249_023_02730_5
crossref_primary_10_1021_acs_molpharmaceut_7b01057
crossref_primary_10_1021_acs_jpcc_2c01871
crossref_primary_10_3390_pharmaceutics13091467
crossref_primary_10_1021_acs_molpharmaceut_8b00970
crossref_primary_10_1016_j_ijpharm_2018_12_092
crossref_primary_10_1021_acs_molpharmaceut_2c00479
crossref_primary_10_1002_mrc_5390
crossref_primary_10_1016_j_ijpharm_2016_12_014
crossref_primary_10_1016_j_ijpharm_2024_124438
crossref_primary_10_1016_j_ajps_2023_100834
crossref_primary_10_1021_acs_molpharmaceut_7b00993
crossref_primary_10_1007_s40005_017_0361_5
crossref_primary_10_1016_j_jddst_2023_105158
crossref_primary_10_3390_pharmaceutics11080372
crossref_primary_10_1021_acs_cgd_6b01271
crossref_primary_10_1016_j_jconrel_2017_03_003
crossref_primary_10_1208_s12249_023_02622_8
crossref_primary_10_1080_01932691_2023_2284883
crossref_primary_10_1039_D2AN01903E
crossref_primary_10_1016_j_ijpharm_2020_119376
crossref_primary_10_3390_pharmaceutics14102158
crossref_primary_10_3390_polym15132912
crossref_primary_10_1021_acs_molpharmaceut_9b00601
crossref_primary_10_1080_03639045_2017_1304960
crossref_primary_10_1007_s11095_018_2346_0
crossref_primary_10_1021_acs_molpharmaceut_0c00268
crossref_primary_10_1007_s11095_020_02813_z
crossref_primary_10_1016_j_ijpharm_2020_119545
crossref_primary_10_1021_acs_molpharmaceut_0c00790
crossref_primary_10_1208_s12249_019_1370_7
crossref_primary_10_1016_j_ijpharm_2020_119300
crossref_primary_10_1021_acs_cgd_9b01571
crossref_primary_10_3390_polym14061241
crossref_primary_10_1016_j_ijpharm_2023_123504
crossref_primary_10_1016_j_jmr_2022_107352
crossref_primary_10_1016_j_ijpharm_2016_01_026
crossref_primary_10_1590_s2175_97902020000117797
crossref_primary_10_1016_j_xphs_2024_04_006
crossref_primary_10_1021_acs_molpharmaceut_1c00427
crossref_primary_10_1016_j_ijpharm_2017_01_043
crossref_primary_10_1038_srep46367
crossref_primary_10_1016_j_ijpharm_2021_121082
crossref_primary_10_1021_acs_molpharmaceut_0c00317
Cites_doi 10.1016/S0928-0987(00)00173-1
10.1006/jmra.1994.1208
10.3109/03639049809082722
10.1016/0040-6031(94)80024-3
10.1002/jps.21174
10.1016/j.ssnmr.2006.06.001
10.1016/S0169-409X(01)00098-9
10.1246/bcsj.64.688
10.1021/mp100205g
10.1038/298729a0
10.1021/jf060188r
10.1039/c1ce05183k
10.1002/jps.23358
10.1006/jmre.1999.1896
10.1063/1.1677439
10.1023/A:1015834715152
10.1016/0926-2040(93)90032-I
10.1002/jps.23075
10.1016/j.ejps.2005.04.011
10.1016/0022-2364(77)90260-8
10.1021/ma60061a021
10.1021/mp050004g
10.1021/ja0541332
10.1021/js9601896
10.1007/s11095-011-0655-7
10.1021/jm801331y
10.1023/A:1018967717781
10.1021/mp400498n
10.1016/0022-2364(82)90199-8
ContentType Journal Article
Copyright Copyright © 2015 American Chemical Society
Copyright_xml – notice: Copyright © 2015 American Chemical Society
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1021/mp500692a
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1543-8392
EndPage 866
ExternalDocumentID 10_1021_mp500692a
25585133
d131696349
Genre Journal Article
GroupedDBID -
123
4.4
53G
55A
7~N
AABXI
ABMVS
ABUCX
ACGFS
ACS
AEESW
AENEX
AFEFF
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
CS3
DU5
EBS
ED
ED~
EJD
F5P
GNL
H~9
IH9
JG
JG~
LG6
P2P
RNS
ROL
UI2
VF5
VG9
W1F
X
---
-~X
5VS
ABJNI
ABQRX
ADHLV
AHGAQ
BAANH
CGR
CUPRZ
CUY
CVF
ECM
EIF
GGK
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-a381t-887c9eaceb90f54e48ca40e1f155de73d1e61e4729aeac0e868e6c5e85a258c33
IEDL.DBID ACS
ISSN 1543-8384
IngestDate Fri Aug 16 08:48:26 EDT 2024
Fri Aug 23 03:16:40 EDT 2024
Sat Sep 28 08:05:29 EDT 2024
Thu Aug 27 13:41:59 EDT 2020
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords dissolution rate
hydrogen bonding
ionic interaction
amorphous
solid-state NMR
salt
solid dispersion
relaxation
lapatinib
physical stability
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a381t-887c9eaceb90f54e48ca40e1f155de73d1e61e4729aeac0e868e6c5e85a258c33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 25585133
PQID 1660433330
PQPubID 23479
PageCount 10
ParticipantIDs proquest_miscellaneous_1660433330
crossref_primary_10_1021_mp500692a
pubmed_primary_25585133
acs_journals_10_1021_mp500692a
ProviderPackageCode JG~
55A
AABXI
GNL
VF5
7~N
VG9
W1F
ACS
AEESW
AFEFF
ABMVS
ABUCX
IH9
AQSVZ
ED~
UI2
PublicationCentury 2000
PublicationDate 2015-03-02
PublicationDateYYYYMMDD 2015-03-02
PublicationDate_xml – month: 03
  year: 2015
  text: 2015-03-02
  day: 02
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Molecular pharmaceutics
PublicationTitleAlternate Mol. Pharmaceutics
PublicationYear 2015
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References Yuan X. (ref12/cit12) 2014; 11
Mura P. (ref23/cit23) 1998; 24
Bugay D. E. (ref10/cit10) 1993; 10
Dixon W. T. (ref18/cit18) 1982; 49
Barich D. H. (ref21/cit21) 2006; 30
Li Z. J. (ref30/cit30) 2006; 128
Metz G. (ref15/cit15) 1994; 110
Van den Mooter G. (ref4/cit4) 2001; 12
Kojima T. (ref6/cit6) 2012; 29
Hayashi S. (ref22/cit22) 1991; 64
Laurence C. (ref13/cit13) 2009; 52
Liu H. (ref7/cit7) 2012; 101
Fung B. M. (ref20/cit20) 2000; 142
Stejskal E. O. (ref17/cit17) 1977; 28
Weuts I. (ref9/cit9) 2005; 25
Pines A. (ref16/cit16) 1972; 56
Liu Y. (ref28/cit28) 2006; 54
Wegiel L. A. (ref8/cit8) 2013; 102
Kovacic T. (ref27/cit27) 1994; 231
Chokshi R. J. (ref5/cit5) 2008; 97
Forster A. (ref26/cit26) 2003; 58
Couchman P. R. (ref25/cit25) 1978; 11
Oksanen C. A. (ref3/cit3) 1990; 7
Yu L. (ref2/cit2) 2001; 48
Song Z. (ref19/cit19) 1993; 2
Couchman P. R. (ref24/cit24) 1982; 298
Hancock B. C. (ref1/cit1) 1997; 86
Van Eerdenbrugh B. (ref14/cit14) 2011; 13
Pham T. N. (ref11/cit11) 2010; 7
Gupta P. (ref29/cit29) 2005; 2
References_xml – volume: 12
  start-page: 261
  issue: 3
  year: 2001
  ident: ref4/cit4
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/S0928-0987(00)00173-1
  contributor:
    fullname: Van den Mooter G.
– volume: 58
  start-page: 838
  issue: 11
  year: 2003
  ident: ref26/cit26
  publication-title: Pharmazie
  contributor:
    fullname: Forster A.
– volume: 110
  start-page: 219
  issue: 2
  year: 1994
  ident: ref15/cit15
  publication-title: J. Magn. Reson., Ser. A
  doi: 10.1006/jmra.1994.1208
  contributor:
    fullname: Metz G.
– volume: 24
  start-page: 747
  issue: 8
  year: 1998
  ident: ref23/cit23
  publication-title: Drug Dev. Ind. Pharm.
  doi: 10.3109/03639049809082722
  contributor:
    fullname: Mura P.
– volume: 231
  start-page: 215
  issue: 1
  year: 1994
  ident: ref27/cit27
  publication-title: Thermochim. Acta
  doi: 10.1016/0040-6031(94)80024-3
  contributor:
    fullname: Kovacic T.
– volume: 97
  start-page: 2286
  issue: 6
  year: 2008
  ident: ref5/cit5
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.21174
  contributor:
    fullname: Chokshi R. J.
– volume: 30
  start-page: 125
  issue: 3
  year: 2006
  ident: ref21/cit21
  publication-title: Solid State Nucl. Magn. Reson.
  doi: 10.1016/j.ssnmr.2006.06.001
  contributor:
    fullname: Barich D. H.
– volume: 48
  start-page: 27
  issue: 1
  year: 2001
  ident: ref2/cit2
  publication-title: Adv. Drug Delivery Rev.
  doi: 10.1016/S0169-409X(01)00098-9
  contributor:
    fullname: Yu L.
– volume: 64
  start-page: 688
  issue: 2
  year: 1991
  ident: ref22/cit22
  publication-title: Bull. Chem. Soc. Jpn.
  doi: 10.1246/bcsj.64.688
  contributor:
    fullname: Hayashi S.
– volume: 7
  start-page: 1667
  issue: 5
  year: 2010
  ident: ref11/cit11
  publication-title: Mol. Pharmaceutics
  doi: 10.1021/mp100205g
  contributor:
    fullname: Pham T. N.
– volume: 298
  start-page: 729
  issue: 5876
  year: 1982
  ident: ref24/cit24
  publication-title: Nature
  doi: 10.1038/298729a0
  contributor:
    fullname: Couchman P. R.
– volume: 54
  start-page: 5701
  issue: 16
  year: 2006
  ident: ref28/cit28
  publication-title: J. Agric. Food Chem.
  doi: 10.1021/jf060188r
  contributor:
    fullname: Liu Y.
– volume: 13
  start-page: 6171
  issue: 20
  year: 2011
  ident: ref14/cit14
  publication-title: CrystEngComm
  doi: 10.1039/c1ce05183k
  contributor:
    fullname: Van Eerdenbrugh B.
– volume: 102
  start-page: 171
  issue: 1
  year: 2013
  ident: ref8/cit8
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.23358
  contributor:
    fullname: Wegiel L. A.
– volume: 142
  start-page: 97
  issue: 1
  year: 2000
  ident: ref20/cit20
  publication-title: J. Magn. Reson.
  doi: 10.1006/jmre.1999.1896
  contributor:
    fullname: Fung B. M.
– volume: 56
  start-page: 1776
  issue: 4
  year: 1972
  ident: ref16/cit16
  publication-title: J. Chem. Phys.
  doi: 10.1063/1.1677439
  contributor:
    fullname: Pines A.
– volume: 7
  start-page: 654
  issue: 6
  year: 1990
  ident: ref3/cit3
  publication-title: Pharm. Res.
  doi: 10.1023/A:1015834715152
  contributor:
    fullname: Oksanen C. A.
– volume: 2
  start-page: 143
  issue: 3
  year: 1993
  ident: ref19/cit19
  publication-title: Solid State Nucl. Magn. Reson.
  doi: 10.1016/0926-2040(93)90032-I
  contributor:
    fullname: Song Z.
– volume: 101
  start-page: 2204
  issue: 6
  year: 2012
  ident: ref7/cit7
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.23075
  contributor:
    fullname: Liu H.
– volume: 25
  start-page: 387
  issue: 4
  year: 2005
  ident: ref9/cit9
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/j.ejps.2005.04.011
  contributor:
    fullname: Weuts I.
– volume: 28
  start-page: 105
  issue: 1
  year: 1977
  ident: ref17/cit17
  publication-title: J. Magn. Reson. (1969–1992)
  doi: 10.1016/0022-2364(77)90260-8
  contributor:
    fullname: Stejskal E. O.
– volume: 11
  start-page: 117
  issue: 1
  year: 1978
  ident: ref25/cit25
  publication-title: Macromolecules
  doi: 10.1021/ma60061a021
  contributor:
    fullname: Couchman P. R.
– volume: 2
  start-page: 384
  issue: 5
  year: 2005
  ident: ref29/cit29
  publication-title: Mol. Pharmaceutics
  doi: 10.1021/mp050004g
  contributor:
    fullname: Gupta P.
– volume: 128
  start-page: 8199
  issue: 25
  year: 2006
  ident: ref30/cit30
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/ja0541332
  contributor:
    fullname: Li Z. J.
– volume: 86
  start-page: 1
  issue: 1
  year: 1997
  ident: ref1/cit1
  publication-title: J. Pharm. Sci.
  doi: 10.1021/js9601896
  contributor:
    fullname: Hancock B. C.
– volume: 29
  start-page: 2777
  issue: 10
  year: 2012
  ident: ref6/cit6
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-011-0655-7
  contributor:
    fullname: Kojima T.
– volume: 52
  start-page: 4073
  issue: 14
  year: 2009
  ident: ref13/cit13
  publication-title: J. Med. Chem.
  doi: 10.1021/jm801331y
  contributor:
    fullname: Laurence C.
– volume: 10
  start-page: 317
  issue: 3
  year: 1993
  ident: ref10/cit10
  publication-title: Pharm. Res.
  doi: 10.1023/A:1018967717781
  contributor:
    fullname: Bugay D. E.
– volume: 11
  start-page: 329
  issue: 1
  year: 2014
  ident: ref12/cit12
  publication-title: Mol. Pharmaceutics
  doi: 10.1021/mp400498n
  contributor:
    fullname: Yuan X.
– volume: 49
  start-page: 341
  issue: 2
  year: 1982
  ident: ref18/cit18
  publication-title: J. Magn. Reson. (1969–1992)
  doi: 10.1016/0022-2364(82)90199-8
  contributor:
    fullname: Dixon W. T.
SSID ssj0024523
Score 2.5022805
Snippet This study investigated the presence of specific drug–excipient interactions in amorphous solid dispersions of lapatinib (LB) and four commonly used...
This study investigated the presence of specific drug-excipient interactions in amorphous solid dispersions of lapatinib (LB) and four commonly used...
SourceID proquest
crossref
pubmed
acs
SourceType Aggregation Database
Index Database
Publisher
StartPage 857
SubjectTerms Biological Availability
Biopharmaceutics
Crystallization
Drug Carriers - chemistry
Drug Stability
Excipients
Humans
Hydrogen Bonding
Magnetic Resonance Spectroscopy
Methylcellulose - analogs & derivatives
Methylcellulose - chemistry
Polyethylene Glycols - chemistry
Polyvinyls - chemistry
Povidone - analogs & derivatives
Povidone - chemistry
Quinazolines - administration & dosage
Quinazolines - chemistry
Quinazolines - pharmacokinetics
Solubility
Title Investigation of Drug–Excipient Interactions in Lapatinib Amorphous Solid Dispersions Using Solid-State NMR Spectroscopy
URI http://dx.doi.org/10.1021/mp500692a
https://www.ncbi.nlm.nih.gov/pubmed/25585133
https://search.proquest.com/docview/1660433330
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3JTsMwELUQXLiwL2WpzCJOBGLHTs2xoiCEACEKErfIdlwUAUlFUon2xD_wh3wJY6cLCArXyIksz4znTWbmDUK7zICamJqxqUEIUIgEkwqpLXIMYw4qpKlj27-8Cs_u2Pk9v59AO2My-JQcPre5pdOlAIKmKPhDG2HVj5sjQj3uZrgBFAg8EQg2oA_6-qp1PTr_7nrG4EnnV05nUWPQnVOWkzwedAp1oHs_yRr_2vIcmunjSlwvFWEeTZh0Ae1dl8TU3X18O-qzyvfxHr4eUVZ3F1HvC91GluKshRsvnYePt_eTV520bcskdr8Oyy6IHCcpvpC2FjtNFK4_ZyCsrJPjZvaUxLiRWPbx3C10FQnlc8_hWnx1eYPt0PvC0mhm7e4Sujs9uT0-8_pTGTwJ3r3w4FbSR3BdG3XktzgzTGjJfENagExiUwtiYkJiGIB2Cat8I0JhQs2N4JJyoYNgGU2mWWpWESZCxgyOiTGlmJItQYn0VUy1giCKy7iCqiC2qG9VeeQS5pREw_OtoO2BRKN2yc7x26KtgawjsB2bEJGpgVOJSBha_rYg8CtopVSC4Wcg1BJ29s3af3tYR9MAorirS6MbaLJ46ZhNACqFqjpF_QTqO-RO
link.rule.ids 315,786,790,2782,27107,27955,27956,57091,57141
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT8MwDI4QHODC-zGeASFOFJo26cJxGqAB2zSxIXGrkjRDFdBOdJMYJ_4D_5BfgpNubCAQXKs0shwn_hLbnxHapxrMRBe1CQ3CBYUI2FKBZ5Icg4iBCSnPsu3X6kHlhl7estsBTY6phQEhMpgps0H8EbsAOX7sMMOq6wEWmmJF8HIGBpWbI149Zlu5ASLwHe5zOmQRGv_VeCCVffVAv8BK617O5_I-RVYwm1Vyf9TryiP18o2z8X-Sz6PZAcrEpdwsFtCEThbRQSOnqe4f4tao6io7xAe4MSKw7i-hlzHyjTTBaRufPvXu3l_fzp5V3DEFlNg-JOY1ERmOE1wVJjM7iSUuPaawdGkvw830IY7waWy4yDM70OYn5N8di3JxvXaNmx3bicfUx_SX0c35WatccQY9GhwBvr7rwBmlTuDw1vLEbTOqKVeCupq0AadEuuhHRAdEU4DwAka5mgdcB4ppzoTHuPL9FTSZpIleQ5hwEVFQE6VSUina3CPClZGnJFypmIgKaBvUGw72WBba8LlHwk_9FtDecGHDTs7V8dOg3eGSh7CTTHhEJBq0EpIgMGxuvu8W0GpuC5_TwMWLm04463_JsIOmK61aNaxe1K820AzAK2Yz1rxNNNl96uktgDBduW1t9wPOZuy5
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1fT9swELcQSIiXjT8bdINi0MQTgTixU_NYtVT87SpKpb5FtuOgiJFEpJUoT_sO-4Z8Es5O2rJpE3uNHOt0vsv9Lr77HULfqAYz0Q1trgYhQSECXCrwTJFjEDEwIeVZtv3rbnA2oBdDNqwSRdMLA0IUsFNhL_GNV-dRXDEMkOOHnBlmXQ_w0BJrEGocsdnqz7n1mB3nBqjAd7jP6ZRJ6O2rJgqp4vco9A9oaUNM5yP6PhPOVpbcH41H8kg9_8Hb-P_Sr6IPFdrEzdI81tCCTtfRQa-kq54c4tt591VxiA9wb05kPdlAz29IOLIUZzFuP47vXn7-On1SSW4aKbH9oVj2RhQ4SfGVMBXaaSJx8yGDI8zGBe5nP5IItxPDSV7YhbZOoXzuWLSLu9c3uJ_biTymT2byCQ06p7etM6ea1eAIiPkjB75V6gQ-4lqeuDGjmnIlqKtJDHgl0g0_IjogmgKUF7DK1TzgOlBMcyY8xpXvf0aLaZbqLYQJFxEFNVEqJZUi5h4Rrow8JSG1YiKqoTqoOKx8rQjtNbpHwpl-a2h_erhhXnJ2_G3R3vTYQ_Aoc00iUg1aCUkQGFY333draLO0h9k2kIBxMxHny3sy7KLlXrsTXp13L7-iFUBZzBauedtocfQ41juAZEaybs33FVxv7zM
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Investigation+of+drug-excipient+interactions+in+lapatinib+amorphous+solid+dispersions+using+solid-state+NMR+spectroscopy&rft.jtitle=Molecular+pharmaceutics&rft.au=Song%2C+Yang&rft.au=Yang%2C+Xinghao&rft.au=Chen%2C+Xin&rft.au=Nie%2C+Haichen&rft.date=2015-03-02&rft.eissn=1543-8392&rft.volume=12&rft.issue=3&rft.spage=857&rft_id=info:doi/10.1021%2Fmp500692a&rft_id=info%3Apmid%2F25585133&rft.externalDocID=25585133
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1543-8384&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1543-8384&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1543-8384&client=summon